Table 1.
Study characteristic of included studies
| Study, Author | Place | Study Design | Population | Intervention | Control or SOC | Virological cure (n) | Outcome |
|---|---|---|---|---|---|---|---|
| Cai Q, 2020[7] | China | Open control trial | RT-PCR confirmed COVID-19 (noncritically ill) | FPV (400/100 mg) BD (n=35) (day 1: 1600 mg twice daily; days 2-14: 600 mg twice daily | SOC (LPV/RTV: 1600 mg twice daily on day 1 and 600 mg twice daily on days 2-14) n=45 (days 1-14: 400 mg/100 mg twice daily) |
FPV: 32 LPV/RTV: 28 |
FPV showed better therapeutic responses on COVID-19 in terms of disease progression and viral clearance |
| Chen C, 2020[6] | China | RCT - multicenter trial | RT-PCR confirmed severe COVID-19 | FPV (n=116) (1600 mg*2/first day, followed by 600 mg*2/day) for 10 days | Arbidol (n=120) Conventional therapy plus umifenovir (arbidol) (200 mg*3/day |
FPV: 71 Arbidol: 62 |
FPV did not significantly improve the clinical recovery rate at day 7, compared to Arbidol |
| Lou Y, 2020[12] | China | Open control trial | RT-PCR confirmed severe COVID-19 | FPV (n=9) 1600 mg or 2200 mg orally, followed by 600 mg each time, 3 times a day, and the duration of administration was not>14 days |
Baloxavir marboxil group (n=10) and control group (n=10) (80 mg once a day orally on day 1 and day 4; for patients who are still positive in the virological test, they can be given again on day) | FPV: 7 Baloxavir: 7 Control: 10 |
Author did not found a significant difference as compared to control or SIOC in viral negativity on day 14 |
| Ivashchenko AA[12] | Russia | Multicenter, open-label, randomized (Phase II/III) | Mild to moderate COVID-19 | FPV (n=20): AVIFAVIR 1600 mg BID on day 1, followed by 600 mg BID on days 2–14 FPV (n=20): AVIFAVIR 1800 mg BID on day 1, followed by 800 mg BID on days 2-14 |
SOC (n=20): Russian guidelines for the treatment of COVID-19 | FPV: 37 SOC: 16 |
FPV demonstrated rapid antiviral response against SARS-CoV |
RT-PCR: Real-time polymerase chain reaction, RCT: Randomized controlled trial, FPV: Favipiravir, SOC: Standard of care, LPV/RTV: Lopinavir/ritonavir, SARS-CoV: Severe acute respiratory syndrome coronavirus